Presentation is loading. Please wait.

Presentation is loading. Please wait.

Induction of long-lived allergen-specific plasma cells by mucosal allergen challenge  Elke O. Luger, PhD, Verena Fokuhl, MSc, Michael Wegmann, PhD, Melanie.

Published byJune Elliott Modified over 5 years ago

Similar presentations

Presentation on theme: "Induction of long-lived allergen-specific plasma cells by mucosal allergen challenge  Elke O. Luger, PhD, Verena Fokuhl, MSc, Michael Wegmann, PhD, Melanie."— Presentation transcript:

1 Induction of long-lived allergen-specific plasma cells by mucosal allergen challenge 
Elke O. Luger, PhD, Verena Fokuhl, MSc, Michael Wegmann, PhD, Melanie Abram, MSc, Kati Tillack, MSc, Gernot Achatz, PhD, Rudolf A. Manz, PhD, Margitta Worm, MD, Andreas Radbruch, PhD, Harald Renz, MD  Journal of Allergy and Clinical Immunology  Volume 124, Issue 4, Pages e4 (October 2009) DOI: /j.jaci Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Cyclophosphamide (CyP)-resistant ovalbumin (OVA)-specific PCs in bone marrow and spleen. A, Experimental setup. B, Survival of OVA-specific immunoglobulin ASCs detected by ELISpot at day 100. C, Specific effect of CyP shown by reduction of ASCs at day 70. Each symbol represents the number of ASCs per organ per single mouse. Data from 2 independent experiments, 16 mice each. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 1 Cyclophosphamide (CyP)-resistant ovalbumin (OVA)-specific PCs in bone marrow and spleen. A, Experimental setup. B, Survival of OVA-specific immunoglobulin ASCs detected by ELISpot at day 100. C, Specific effect of CyP shown by reduction of ASCs at day 70. Each symbol represents the number of ASCs per organ per single mouse. Data from 2 independent experiments, 16 mice each. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 1 Cyclophosphamide (CyP)-resistant ovalbumin (OVA)-specific PCs in bone marrow and spleen. A, Experimental setup. B, Survival of OVA-specific immunoglobulin ASCs detected by ELISpot at day 100. C, Specific effect of CyP shown by reduction of ASCs at day 70. Each symbol represents the number of ASCs per organ per single mouse. Data from 2 independent experiments, 16 mice each. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 1 Cyclophosphamide (CyP)-resistant ovalbumin (OVA)-specific PCs in bone marrow and spleen. A, Experimental setup. B, Survival of OVA-specific immunoglobulin ASCs detected by ELISpot at day 100. C, Specific effect of CyP shown by reduction of ASCs at day 70. Each symbol represents the number of ASCs per organ per single mouse. Data from 2 independent experiments, 16 mice each. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig 1 Cyclophosphamide (CyP)-resistant ovalbumin (OVA)-specific PCs in bone marrow and spleen. A, Experimental setup. B, Survival of OVA-specific immunoglobulin ASCs detected by ELISpot at day 100. C, Specific effect of CyP shown by reduction of ASCs at day 70. Each symbol represents the number of ASCs per organ per single mouse. Data from 2 independent experiments, 16 mice each. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7 Fig 1 Cyclophosphamide (CyP)-resistant ovalbumin (OVA)-specific PCs in bone marrow and spleen. A, Experimental setup. B, Survival of OVA-specific immunoglobulin ASCs detected by ELISpot at day 100. C, Specific effect of CyP shown by reduction of ASCs at day 70. Each symbol represents the number of ASCs per organ per single mouse. Data from 2 independent experiments, 16 mice each. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

8 Fig 1 Cyclophosphamide (CyP)-resistant ovalbumin (OVA)-specific PCs in bone marrow and spleen. A, Experimental setup. B, Survival of OVA-specific immunoglobulin ASCs detected by ELISpot at day 100. C, Specific effect of CyP shown by reduction of ASCs at day 70. Each symbol represents the number of ASCs per organ per single mouse. Data from 2 independent experiments, 16 mice each. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

9 Fig 2 Immigration and kinetic of ovalbumin (OVA)-specific IgG1, IgA, and IgE ASCs. A, Experimental setup. B, Lung ELISpot of OVA-sensitized (●) and OVA-sensitized plus OVA aerosol–challenged mice (▴). C, Bone marrow/spleen ELISpot of OVA-sensitized (●) and sensitized plus OVA-challenged mice (▴). i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

10 Fig 2 Immigration and kinetic of ovalbumin (OVA)-specific IgG1, IgA, and IgE ASCs. A, Experimental setup. B, Lung ELISpot of OVA-sensitized (●) and OVA-sensitized plus OVA aerosol–challenged mice (▴). C, Bone marrow/spleen ELISpot of OVA-sensitized (●) and sensitized plus OVA-challenged mice (▴). i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

11 Fig 2 Immigration and kinetic of ovalbumin (OVA)-specific IgG1, IgA, and IgE ASCs. A, Experimental setup. B, Lung ELISpot of OVA-sensitized (●) and OVA-sensitized plus OVA aerosol–challenged mice (▴). C, Bone marrow/spleen ELISpot of OVA-sensitized (●) and sensitized plus OVA-challenged mice (▴). i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

12 Fig 2 Immigration and kinetic of ovalbumin (OVA)-specific IgG1, IgA, and IgE ASCs. A, Experimental setup. B, Lung ELISpot of OVA-sensitized (●) and OVA-sensitized plus OVA aerosol–challenged mice (▴). C, Bone marrow/spleen ELISpot of OVA-sensitized (●) and sensitized plus OVA-challenged mice (▴). i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

13 Fig 2 Immigration and kinetic of ovalbumin (OVA)-specific IgG1, IgA, and IgE ASCs. A, Experimental setup. B, Lung ELISpot of OVA-sensitized (●) and OVA-sensitized plus OVA aerosol–challenged mice (▴). C, Bone marrow/spleen ELISpot of OVA-sensitized (●) and sensitized plus OVA-challenged mice (▴). i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

14 Fig 2 Immigration and kinetic of ovalbumin (OVA)-specific IgG1, IgA, and IgE ASCs. A, Experimental setup. B, Lung ELISpot of OVA-sensitized (●) and OVA-sensitized plus OVA aerosol–challenged mice (▴). C, Bone marrow/spleen ELISpot of OVA-sensitized (●) and sensitized plus OVA-challenged mice (▴). i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

15 Fig 2 Immigration and kinetic of ovalbumin (OVA)-specific IgG1, IgA, and IgE ASCs. A, Experimental setup. B, Lung ELISpot of OVA-sensitized (●) and OVA-sensitized plus OVA aerosol–challenged mice (▴). C, Bone marrow/spleen ELISpot of OVA-sensitized (●) and sensitized plus OVA-challenged mice (▴). i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

16 Fig 2 Immigration and kinetic of ovalbumin (OVA)-specific IgG1, IgA, and IgE ASCs. A, Experimental setup. B, Lung ELISpot of OVA-sensitized (●) and OVA-sensitized plus OVA aerosol–challenged mice (▴). C, Bone marrow/spleen ELISpot of OVA-sensitized (●) and sensitized plus OVA-challenged mice (▴). i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

17 Fig 2 Immigration and kinetic of ovalbumin (OVA)-specific IgG1, IgA, and IgE ASCs. A, Experimental setup. B, Lung ELISpot of OVA-sensitized (●) and OVA-sensitized plus OVA aerosol–challenged mice (▴). C, Bone marrow/spleen ELISpot of OVA-sensitized (●) and sensitized plus OVA-challenged mice (▴). i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

18 Fig 2 Immigration and kinetic of ovalbumin (OVA)-specific IgG1, IgA, and IgE ASCs. A, Experimental setup. B, Lung ELISpot of OVA-sensitized (●) and OVA-sensitized plus OVA aerosol–challenged mice (▴). C, Bone marrow/spleen ELISpot of OVA-sensitized (●) and sensitized plus OVA-challenged mice (▴). i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

19 Fig 2 Immigration and kinetic of ovalbumin (OVA)-specific IgG1, IgA, and IgE ASCs. A, Experimental setup. B, Lung ELISpot of OVA-sensitized (●) and OVA-sensitized plus OVA aerosol–challenged mice (▴). C, Bone marrow/spleen ELISpot of OVA-sensitized (●) and sensitized plus OVA-challenged mice (▴). i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

20 Fig 3 Ovalbumin (OVA) aerosol boosts systemic immune response. A, Experimental setup. B, Cryostaining of splenic IgE PCs with (□) and without (●) OVA inhalation. n = Representative IgE PC staining. C, OVA-specific PCs in spleen with and without 2 weeks of OVA aerosol treatment. Gated on CD138. D, Increase of OVA-IgE ASCs in bone marrow during OVA aerosol by ELISpot. n = 6. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

21 Fig 3 Ovalbumin (OVA) aerosol boosts systemic immune response. A, Experimental setup. B, Cryostaining of splenic IgE PCs with (□) and without (●) OVA inhalation. n = Representative IgE PC staining. C, OVA-specific PCs in spleen with and without 2 weeks of OVA aerosol treatment. Gated on CD138. D, Increase of OVA-IgE ASCs in bone marrow during OVA aerosol by ELISpot. n = 6. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

22 Fig 3 Ovalbumin (OVA) aerosol boosts systemic immune response. A, Experimental setup. B, Cryostaining of splenic IgE PCs with (□) and without (●) OVA inhalation. n = Representative IgE PC staining. C, OVA-specific PCs in spleen with and without 2 weeks of OVA aerosol treatment. Gated on CD138. D, Increase of OVA-IgE ASCs in bone marrow during OVA aerosol by ELISpot. n = 6. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

23 Fig 3 Ovalbumin (OVA) aerosol boosts systemic immune response. A, Experimental setup. B, Cryostaining of splenic IgE PCs with (□) and without (●) OVA inhalation. n = Representative IgE PC staining. C, OVA-specific PCs in spleen with and without 2 weeks of OVA aerosol treatment. Gated on CD138. D, Increase of OVA-IgE ASCs in bone marrow during OVA aerosol by ELISpot. n = 6. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

24 Fig 3 Ovalbumin (OVA) aerosol boosts systemic immune response. A, Experimental setup. B, Cryostaining of splenic IgE PCs with (□) and without (●) OVA inhalation. n = Representative IgE PC staining. C, OVA-specific PCs in spleen with and without 2 weeks of OVA aerosol treatment. Gated on CD138. D, Increase of OVA-IgE ASCs in bone marrow during OVA aerosol by ELISpot. n = 6. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

25 Fig 4 Survival of long-lived, ovalbumin (OVA)-specific PCs at day 100 after aerosol challenge. A, Experimental setup. B, Long-lived OVA-specific ASCs at day 100 in bone marrow, spleen, and lung, detected by ELISpot. (●) Systemically immunized, (○) systemically immunized plus cyclophosphamide (CyP)-treated (days 74-77), (▴) systemically immunized plus aerosol-challenged, (Δ) systemically immunized, aerosol and cyclophosphamide–treated. n = 8 per group. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

26 Fig 4 Survival of long-lived, ovalbumin (OVA)-specific PCs at day 100 after aerosol challenge. A, Experimental setup. B, Long-lived OVA-specific ASCs at day 100 in bone marrow, spleen, and lung, detected by ELISpot. (●) Systemically immunized, (○) systemically immunized plus cyclophosphamide (CyP)-treated (days 74-77), (▴) systemically immunized plus aerosol-challenged, (Δ) systemically immunized, aerosol and cyclophosphamide–treated. n = 8 per group. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

27 Fig 4 Survival of long-lived, ovalbumin (OVA)-specific PCs at day 100 after aerosol challenge. A, Experimental setup. B, Long-lived OVA-specific ASCs at day 100 in bone marrow, spleen, and lung, detected by ELISpot. (●) Systemically immunized, (○) systemically immunized plus cyclophosphamide (CyP)-treated (days 74-77), (▴) systemically immunized plus aerosol-challenged, (Δ) systemically immunized, aerosol and cyclophosphamide–treated. n = 8 per group. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

28 Fig 4 Survival of long-lived, ovalbumin (OVA)-specific PCs at day 100 after aerosol challenge. A, Experimental setup. B, Long-lived OVA-specific ASCs at day 100 in bone marrow, spleen, and lung, detected by ELISpot. (●) Systemically immunized, (○) systemically immunized plus cyclophosphamide (CyP)-treated (days 74-77), (▴) systemically immunized plus aerosol-challenged, (Δ) systemically immunized, aerosol and cyclophosphamide–treated. n = 8 per group. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

29 Fig 4 Survival of long-lived, ovalbumin (OVA)-specific PCs at day 100 after aerosol challenge. A, Experimental setup. B, Long-lived OVA-specific ASCs at day 100 in bone marrow, spleen, and lung, detected by ELISpot. (●) Systemically immunized, (○) systemically immunized plus cyclophosphamide (CyP)-treated (days 74-77), (▴) systemically immunized plus aerosol-challenged, (Δ) systemically immunized, aerosol and cyclophosphamide–treated. n = 8 per group. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

30 Fig 4 Survival of long-lived, ovalbumin (OVA)-specific PCs at day 100 after aerosol challenge. A, Experimental setup. B, Long-lived OVA-specific ASCs at day 100 in bone marrow, spleen, and lung, detected by ELISpot. (●) Systemically immunized, (○) systemically immunized plus cyclophosphamide (CyP)-treated (days 74-77), (▴) systemically immunized plus aerosol-challenged, (Δ) systemically immunized, aerosol and cyclophosphamide–treated. n = 8 per group. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

31 Fig 4 Survival of long-lived, ovalbumin (OVA)-specific PCs at day 100 after aerosol challenge. A, Experimental setup. B, Long-lived OVA-specific ASCs at day 100 in bone marrow, spleen, and lung, detected by ELISpot. (●) Systemically immunized, (○) systemically immunized plus cyclophosphamide (CyP)-treated (days 74-77), (▴) systemically immunized plus aerosol-challenged, (Δ) systemically immunized, aerosol and cyclophosphamide–treated. n = 8 per group. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

32 Fig 4 Survival of long-lived, ovalbumin (OVA)-specific PCs at day 100 after aerosol challenge. A, Experimental setup. B, Long-lived OVA-specific ASCs at day 100 in bone marrow, spleen, and lung, detected by ELISpot. (●) Systemically immunized, (○) systemically immunized plus cyclophosphamide (CyP)-treated (days 74-77), (▴) systemically immunized plus aerosol-challenged, (Δ) systemically immunized, aerosol and cyclophosphamide–treated. n = 8 per group. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

33 Fig 4 Survival of long-lived, ovalbumin (OVA)-specific PCs at day 100 after aerosol challenge. A, Experimental setup. B, Long-lived OVA-specific ASCs at day 100 in bone marrow, spleen, and lung, detected by ELISpot. (●) Systemically immunized, (○) systemically immunized plus cyclophosphamide (CyP)-treated (days 74-77), (▴) systemically immunized plus aerosol-challenged, (Δ) systemically immunized, aerosol and cyclophosphamide–treated. n = 8 per group. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

34 Fig 4 Survival of long-lived, ovalbumin (OVA)-specific PCs at day 100 after aerosol challenge. A, Experimental setup. B, Long-lived OVA-specific ASCs at day 100 in bone marrow, spleen, and lung, detected by ELISpot. (●) Systemically immunized, (○) systemically immunized plus cyclophosphamide (CyP)-treated (days 74-77), (▴) systemically immunized plus aerosol-challenged, (Δ) systemically immunized, aerosol and cyclophosphamide–treated. n = 8 per group. i.p., Intraperitoneal. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

35 Cyclophosphamide -resistant ovalbumin-specific PCs in bone marrow and spleen. A, Survival of total immunoglobulin ASCs detected by ELISpot at day 100. B, Representative ELISpot. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

36 Cyclophosphamide -resistant ovalbumin-specific PCs in bone marrow and spleen. A, Survival of total immunoglobulin ASCs detected by ELISpot at day 100. B, Representative ELISpot. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

37 Immigration and kinetic of ovalbumin-specific IgG1, IgA, and IgE ASCs
Immigration and kinetic of ovalbumin-specific IgG1, IgA, and IgE ASCs. A, Experimental setup. B, Cryostaining from day 29 of T cells (anti-CD3), B cells (anti-B220), BCR on the surface or in the cytoplasm of B cells/plasmablasts/PCs (anti-κ/λ staining), IgE-positive and IgG-positive B cells and PCs (anti-IgE/anti-IgG). Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

38 Immigration and kinetic of ovalbumin-specific IgG1, IgA, and IgE ASCs
Immigration and kinetic of ovalbumin-specific IgG1, IgA, and IgE ASCs. A, Experimental setup. B, Cryostaining from day 29 of T cells (anti-CD3), B cells (anti-B220), BCR on the surface or in the cytoplasm of B cells/plasmablasts/PCs (anti-κ/λ staining), IgE-positive and IgG-positive B cells and PCs (anti-IgE/anti-IgG). Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

39 Immigration and kinetic of ovalbumin-specific IgG1, IgA, and IgE ASCs
Immigration and kinetic of ovalbumin-specific IgG1, IgA, and IgE ASCs. A, Experimental setup. B, Cryostaining from day 29 of T cells (anti-CD3), B cells (anti-B220), BCR on the surface or in the cytoplasm of B cells/plasmablasts/PCs (anti-κ/λ staining), IgE-positive and IgG-positive B cells and PCs (anti-IgE/anti-IgG). Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

40 Immigration and kinetic of ovalbumin-specific IgG1, IgA, and IgE ASCs
Immigration and kinetic of ovalbumin-specific IgG1, IgA, and IgE ASCs. A, Experimental setup. B, Cryostaining from day 29 of T cells (anti-CD3), B cells (anti-B220), BCR on the surface or in the cytoplasm of B cells/plasmablasts/PCs (anti-κ/λ staining), IgE-positive and IgG-positive B cells and PCs (anti-IgE/anti-IgG). Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

41 Immigration and kinetic of ovalbumin-specific IgG1, IgA, and IgE ASCs
Immigration and kinetic of ovalbumin-specific IgG1, IgA, and IgE ASCs. A, Experimental setup. B, Cryostaining from day 29 of T cells (anti-CD3), B cells (anti-B220), BCR on the surface or in the cytoplasm of B cells/plasmablasts/PCs (anti-κ/λ staining), IgE-positive and IgG-positive B cells and PCs (anti-IgE/anti-IgG). Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

42 Immigration and kinetic of ovalbumin-specific IgG1, IgA, and IgE ASCs
Immigration and kinetic of ovalbumin-specific IgG1, IgA, and IgE ASCs. A, Experimental setup. B, Cryostaining from day 29 of T cells (anti-CD3), B cells (anti-B220), BCR on the surface or in the cytoplasm of B cells/plasmablasts/PCs (anti-κ/λ staining), IgE-positive and IgG-positive B cells and PCs (anti-IgE/anti-IgG). Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

43 Ovalbumin aerosol boosts systemic immune response
Ovalbumin aerosol boosts systemic immune response. Total and ovalbumin-specific ELISA. Data from 2 independent experiments. n = 12 each. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

44 Survival of long-lived, ovalbumin-specific PCs at day 100 after aerosol challenge. Ovalbumin-specific IgE and IgG1 ELISA Data from 2 independent experiments. n = 10. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Induction of long-lived allergen-specific plasma cells by mucosal allergen challenge  Elke O. Luger, PhD, Verena Fokuhl, MSc, Michael Wegmann, PhD, Melanie."

Similar presentations

Selective ablation of mast cells or basophils reduces peanut-induced anaphylaxis in mice  Laurent L. Reber, PhD, Thomas Marichal, DVM, PhD, Kaori Mukai,

Selective ablation of mast cells or basophils reduces peanut-induced anaphylaxis in mice  Laurent L. Reber, PhD, Thomas Marichal, DVM, PhD, Kaori Mukai,
IgE-mediated systemic anaphylaxis and impaired tolerance to food antigens in mice with enhanced IL-4 receptor signaling  Clinton B. Mathias, PhD, Suejy.

IgE-mediated systemic anaphylaxis and impaired tolerance to food antigens in mice with enhanced IL-4 receptor signaling  Clinton B. Mathias, PhD, Suejy.
Effective prevention and therapy of experimental allergic asthma using a GATA-3– specific DNAzyme  Serdar Sel, MD, Michael Wegmann, PhD, Tanja Dicke, MSc,

Effective prevention and therapy of experimental allergic asthma using a GATA-3– specific DNAzyme  Serdar Sel, MD, Michael Wegmann, PhD, Tanja Dicke, MSc,
The activating protein 1 transcription factor basic leucine zipper transcription factor, ATF- like (BATF), regulates lymphocyte- and mast cell–driven immune.

The activating protein 1 transcription factor basic leucine zipper transcription factor, ATF- like (BATF), regulates lymphocyte- and mast cell–driven immune.
Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model  Sylvie Amu, PhD, Sean P.

Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model  Sylvie Amu, PhD, Sean P.
The activating protein 1 transcription factor basic leucine zipper transcription factor, ATF- like (BATF), regulates lymphocyte- and mast cell–driven immune.

The activating protein 1 transcription factor basic leucine zipper transcription factor, ATF- like (BATF), regulates lymphocyte- and mast cell–driven immune.
Essential role of dendritic cell CD80/CD86 costimulation in the induction, but not reactivation, of TH2 effector responses in a mouse model of asthma 

Essential role of dendritic cell CD80/CD86 costimulation in the induction, but not reactivation, of TH2 effector responses in a mouse model of asthma 
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Allergy prevention starts before conception: Maternofetal transfer of tolerance protects against the development of asthma  Tobias Polte, PhD, Christian.

Allergy prevention starts before conception: Maternofetal transfer of tolerance protects against the development of asthma  Tobias Polte, PhD, Christian.
A novel allergen-specific therapy for allergy using CD40-silenced dendritic cells  Motohiko Suzuki, MD, PhD, Xiufen Zheng, PhD, Xusheng Zhang, MD, PhD,

A novel allergen-specific therapy for allergy using CD40-silenced dendritic cells  Motohiko Suzuki, MD, PhD, Xiufen Zheng, PhD, Xusheng Zhang, MD, PhD,
Blocking antibodies induced by immunization with a hypoallergenic parvalbumin mutant reduce allergic symptoms in a mouse model of fish allergy  Raphaela.

Blocking antibodies induced by immunization with a hypoallergenic parvalbumin mutant reduce allergic symptoms in a mouse model of fish allergy  Raphaela.
Selective control of SIRP-α–positive airway dendritic cell trafficking through CD47 is critical for the development of TH2-mediated allergic inflammation 

Selective control of SIRP-α–positive airway dendritic cell trafficking through CD47 is critical for the development of TH2-mediated allergic inflammation 
Ting-ting Zhang, MSc, Klaus Okkenhaug, PhD, Baher F

Ting-ting Zhang, MSc, Klaus Okkenhaug, PhD, Baher F
Oral immunotherapy induces IgG antibodies that act through FcγRIIb to suppress IgE- mediated hypersensitivity  Oliver T. Burton, PhD, Stephanie L. Logsdon,

Oral immunotherapy induces IgG antibodies that act through FcγRIIb to suppress IgE- mediated hypersensitivity  Oliver T. Burton, PhD, Stephanie L. Logsdon,
Expression of IL-4 receptor α on smooth muscle cells is not necessary for development of experimental allergic asthma  Frank Kirstein, PhD, William G.C.

Expression of IL-4 receptor α on smooth muscle cells is not necessary for development of experimental allergic asthma  Frank Kirstein, PhD, William G.C.
Frank Kirstein, PhD, Natalie E

Frank Kirstein, PhD, Natalie E
Pentraxin 3 deletion aggravates allergic inflammation through a TH17-dominant phenotype and enhanced CD4 T-cell survival  Jyoti Balhara, MSc, Lianyu Shan,

Pentraxin 3 deletion aggravates allergic inflammation through a TH17-dominant phenotype and enhanced CD4 T-cell survival  Jyoti Balhara, MSc, Lianyu Shan,
Compartmentalized chemokine-dependent regulatory T-cell inhibition of allergic pulmonary inflammation  Roshi Afshar, PhD, James P. Strassner, BS, Edward.

Compartmentalized chemokine-dependent regulatory T-cell inhibition of allergic pulmonary inflammation  Roshi Afshar, PhD, James P. Strassner, BS, Edward.
Matthew C. Tunis, BSc, Wojciech Dawicki, PhD, Kaitlyn R

Matthew C. Tunis, BSc, Wojciech Dawicki, PhD, Kaitlyn R
IL-33 dysregulates regulatory T cells and impairs established immunologic tolerance in the lungs  Chien-Chang Chen, PhD, Takao Kobayashi, PhD, Koji Iijima,

IL-33 dysregulates regulatory T cells and impairs established immunologic tolerance in the lungs  Chien-Chang Chen, PhD, Takao Kobayashi, PhD, Koji Iijima,

Similar presentations

Ads by Google